Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors.

Strumberg D; Richly H; Hilger RA; Schleucher N; Korfee S; Tewes M; Faghih M; Brendel E; Voliotis D; Haase CG

doi:10.1200/jco.2005.06.124

Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors.

Identifier:nobleid.org/w1/20260526/2C6506CD

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/2C6506CD.svg?ark=w1%2F20260526%2F2C6506CD)](https://nobleid.org/work/w1/20260526/2C6506CD)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work

Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors.

Identifier:nobleid.org/w1/20260526/2C6506CD

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/2C6506CD.svg?ark=w1%2F20260526%2F2C6506CD)](https://nobleid.org/work/w1/20260526/2C6506CD)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work